These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 27881273)

  • 1. The Effects of the New Methodology Application on the Method of Pricing of Drugs-The Case of the Republic of Macedonia.
    Zareski R; Kapedanovska Nestorovska A; Grozdanova A; Dimitrova B; Suturkova LJ; Sterjev Z
    Value Health Reg Issues; 2016 Sep; 10():19-28. PubMed ID: 27881273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price.
    Roughead EE; Kim DS; Ong B; Kemp-Casey A
    WHO South East Asia J Public Health; 2018 Sep; 7(2):99-106. PubMed ID: 30136668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Case Study of Pharmaceutical Pricing in China: Setting the Price for Off-Patent Originators.
    Hu S; Zhang Y; He J; Du L; Xu M; Xie C; Peng Y; Wang L
    Appl Health Econ Health Policy; 2015 Aug; 13 Suppl 1(Suppl 1):S13-20. PubMed ID: 26091710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Evolution of Supply and Demand in Markets for Generic Drugs.
    Frank RG; McGuire TG; Nason I
    Milbank Q; 2021 Sep; 99(3):828-852. PubMed ID: 34075623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of South Korea's new drug-pricing policy on market competition among off-patent drugs.
    Kwon HY; Kim H; Godman B; Reich MR
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(6):1007-14. PubMed ID: 26394767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High prices for generics in Australia - more competition might help.
    Bulfone L
    Aust Health Rev; 2009 May; 33(2):200-14. PubMed ID: 19563309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.
    Mueller MT; Frenzel A
    Eur J Health Econ; 2015 Jan; 16(1):73-82. PubMed ID: 24370790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. European healthcare policies for controlling drug expenditure.
    Ess SM; Schneeweiss S; Szucs TD
    Pharmacoeconomics; 2003; 21(2):89-103. PubMed ID: 12515571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Price regulation and generic competition in the pharmaceutical market.
    Dalen DM; Strøm S; Haabeth T
    Eur J Health Econ; 2006 Sep; 7(3):208-14. PubMed ID: 16841230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generic medicine pricing in Europe: current issues and future perspective.
    Simoens S
    J Med Econ; 2008; 11(1):171-5. PubMed ID: 19450118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.
    Wu J; Xu J; Liu G; Wu J
    Pharmacoeconomics; 2014 Mar; 32(3):293-303. PubMed ID: 24190661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous versus exogenous generic reference pricing for pharmaceuticals.
    Antoñanzas F; Juárez-Castelló CA; Rodríguez-Ibeas R
    Int J Health Econ Manag; 2017 Dec; 17(4):413-432. PubMed ID: 28508248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reforming the Swedish pharmaceuticals market: consequences for costs per defined daily dose.
    Bergman MA; Granlund D; Rudholm N
    Int J Health Econ Manag; 2016 Sep; 16(3):201-214. PubMed ID: 27878673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.